Entrada Therapeutics (NASDAQ:TRDA) Shares Up 4.8%

Entrada Therapeutics, Inc. (NASDAQ:TRDA)’s share price was up 4.8% during trading on Friday . The stock traded as high as $16.53 and last traded at $16.53. Approximately 11,675 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 101,015 shares. The stock had previously closed at $15.77.

Analysts Set New Price Targets

TRDA has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Entrada Therapeutics in a report on Wednesday, August 14th. Oppenheimer reaffirmed an “outperform” rating and set a $25.00 price target on shares of Entrada Therapeutics in a research report on Monday, August 26th.

Entrada Therapeutics Stock Up 4.3 %

The stock has a fifty day moving average of $15.72 and a two-hundred day moving average of $14.82. The stock has a market cap of $611.94 million, a price-to-earnings ratio of 26.11 and a beta of -0.24.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.90. The business had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. Equities research analysts anticipate that Entrada Therapeutics, Inc. will post 0.68 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $14.97, for a total transaction of $47,829.15. Following the transaction, the chief financial officer now owns 76,486 shares in the company, valued at approximately $1,144,995.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Kory James Wentworth sold 3,195 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15. Following the sale, the chief financial officer now directly owns 76,486 shares in the company, valued at approximately $1,144,995.42. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Dipal Doshi sold 1,600 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $17.81, for a total value of $28,496.00. Following the transaction, the chief executive officer now directly owns 334,475 shares in the company, valued at $5,956,999.75. The disclosure for this sale can be found here. Insiders sold a total of 13,636 shares of company stock worth $214,057 over the last ninety days. 7.58% of the stock is owned by company insiders.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in Entrada Therapeutics by 3.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after buying an additional 2,146 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Entrada Therapeutics by 27.5% in the second quarter. Marshall Wace LLP now owns 65,943 shares of the company’s stock worth $940,000 after acquiring an additional 14,220 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Entrada Therapeutics in the second quarter valued at about $636,000. American Century Companies Inc. grew its stake in Entrada Therapeutics by 5.1% during the 2nd quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock valued at $5,486,000 after purchasing an additional 18,625 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Entrada Therapeutics by 135.1% during the 2nd quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock worth $190,000 after purchasing an additional 7,682 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.